Cue Biopharma (CUE) Gets a Buy from Stifel Nicolaus

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Cue Biopharma (CUE – Research Report) today and set a price target of $8.00. The company’s shares closed yesterday at $2.04.

Willey covers the Healthcare sector, focusing on stocks such as Exelixis, Geron, and Incyte. According to TipRanks, Willey has an average return of 8.8% and a 42.97% success rate on recommended stocks.

Cue Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $8.00, a 292.16% upside from current levels. In a report released today, Piper Sandler also reiterated a Buy rating on the stock with a $8.00 price target.

CUE market cap is currently $99.23M and has a P/E ratio of -1.84.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cue Biopharma (CUE) Company Description:

Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.